BMRN - Wells Fargo starts BioMarin at overweight cites activist involvement
2023-11-15 13:49:41 ET
More on BioMarin Pharmaceutical
- BioMarin: Keeping Bullish View After Q3 Earnings
- BioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation
- Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript
- BioMarin could be very 'digestible' to larger cap peers in US/Europe - analyst
- Elliott could push for sale, cost cutting at BioMarin - analyst
For further details see:
Wells Fargo starts BioMarin at overweight, cites activist involvement